News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
News
ASX Small Caps and IPO Weekly Wrap: The week we learned what Woolies is really worth
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Thursday and the ASX200 is flat and porous. I am unhappy… But at least Bega made a lot of cheese
Health & Biotech
PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
News
Closing Bell: Material gains for the ASX on Friday while a good week at work sees Tech Sector gain 7.5pc
Health & Biotech
FDA shows the way for accelerated approval of PharmAust’s monepantel in MND
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners
News
Closing Bell: Local markets in a sulk for the cut that won’t come
Health & Biotech
PharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’
News
ASX January winners: The best 50 stocks as ASX S&P reaches record high
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
News
In Case You Missed It: Project expansions, mineral resources and boardroom appointments ahoy!
Health & Biotech
PharmAust gets ethics committee green light for open-label MND extension study
News
Market Highlights: ‘They could cut rates 15 times’… and 5 ASX small caps to watch
News
